Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Biofil Chemicals & Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:BIOFILCHEM's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.36 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Biofil Chemicals & Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:BIOFILCHEM vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #999999 out of 506 companies in the Drug Manufacturers industry.
Is Biofil Chemicals & Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Biofil Chemicals & Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #999999 out of 506 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #999999 out of 506 companies for 5-Year Yield-on-Cost %. This places Biofil Chemicals & Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹48.09, compared to a current price of ₹32.06 — trading 33.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹32.06 is trading 33.3% below its estimated GF Value™ of ₹48.09.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:BIOFILCHEM:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹48.09 vs. price of ₹32.06 (33.3% below fair value)
No single metric tells the full story. See the NSE:BIOFILCHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
73GF Score
Get the complete analysis for NSE:BIOFILCHEM
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOFILCHEM has been successfully added to your 
